Table 3.
Univariate and multivariate analysis of factors associated with overall survival (OS).
| Characteristics | Univariate † | Multivariate ‡ | ||||||
|---|---|---|---|---|---|---|---|---|
| 1-yr OS, % (95% CI) | 3-yr OS, % (95% CI) | 5-yr OS, % (95% CI) | Median OS, Months (95% CI) | p Value | Hazard Ratio (95% CI) | p Value | ||
| Gender | Male | 87.7 (83.2–92.2) | 62.2 (55.1–69.3) | 48.3 (38.5–58.1) | 56.5 (45.5–67.2) | 0.964 | - | NS |
| Female | 96.9 (90.8–100) | 60.2 (42.6–77.8) | 49.3 (29.3–69.3) | 46.6 (-) | - | |||
| Age, years | <60 | 88.0 (81.7–94.3) | 63.3 (53.3–73.3) | 45.0 (29.1–60.9) | 56.5 (35.1–77.9) | 0.945 | - | NS |
| ≥60 | 89.5 (84.4–94.6) | 60.8 (52.0–69.6) | 49.5 (38.3–60.7) | 55.0 (44.5–65.5) | - | |||
| ECOG PS | 0 | 88.6 (84.5–92.7) | 62.8 (56.1–69.5) | 48.6 (39.4–57.8) | 56.5 (44.9–68.0) | 0.175 | - | NS |
| 1 | 100 (-) | 25.0 (0–65.0) | - (-) | 21.2 (4.1–38.4) | - | |||
| Etiology of LC | HBV | 88.8 (84.3–93.3) | 62.4 (55.0–69.8) | 49.4 (39.2–59.6) | 56.5 (-) | 0.784 | - | NS |
| Others | 89.1 (80.9–97.3) | 60.0 (45.5–74.5) | 44.9 (26.1–63.7) | 55.0 (32.0–78.0) | - | |||
| Child-Pugh Classification | A | 90.4 (86.5–94.3) | 65.3 (58.6–72.0) | 50.5 (41.1–59.9) | 60.3 (-) | <0.001 | 1.000 | 0.016 |
| B7 | 66.7 (42.8–90.6) | 0.91 (0–26.0) | 0.91 (0–26.0) | 17.1 (1.6–32.6) | 2.221 (1.162–4.246) | |||
| AFP, ng/mL | <10 | 92.5 (87.8–97.2) | 74.3 (65.7–82.9) | 56.3 (41.6–71.0) | NR | <0.001 | 1.000 | 0.008 |
| ≥10 | 85.4 (79.1–91.7) | 49.9 (40.5–59.3) | 39.6 (28.6–50.6) | 34.3 (24.4–44.2) | 1.773 (1.158–2.713) | |||
| Tumor size, cm | ≤2 | 94.8 (90.7–98.9) | 79.5 (71.5–87.5) | 64.4 (49.3–7.5) | NR | <0.001 | - | NS |
| >2 | 83.6 (77.1–90.1) | 46.5 (37.1–55.9) | 34.0 (23.6–44.4) | 33.9 (28.4–39.5) | - | |||
| TVT | No | 93.5 (90.0–97.0) | 67.8 (60.4–75.3) | 54.1 (43.9–64.3) | 60.3 (-) | <0.001 | – | NS |
| Branch | 79.3 (60.4–91.4) | 49.0 (29.8–68.2) | 49.0 (29.8–68.2) | 34.3 (-) | ||||
| Main | 73.3 (57.4–89.2) | 38.8 (21.0–56.6) | 18.9 (0–38.1) | 19.4 (6.1–32.8) | - | |||
| mUICC stage | I | 100 (-) | 92.3 (77.8–100) | 69.2 (28.6–100) | NR | <0.001 | 1.000 | |
| II | 94.6 (89.5–99.7) | 83.9 (74.5–93.3) | 65.4 (45.8–85) | NR | 3.186 (0.699–14.525) | 0.134 | ||
| III | 93.4 (88.7–98.1) | 57.0 (46.8–67.2) | 43.8 (31.3–56.3) | 46.6 (34.9–58.4) | 6.563 (1.557–27.669) | 0.010 | ||
| IVA | 68.0 (55.1–80.9) | 33.4 (19.7–47.1) | 26.6 (12.7–40.5) | 19.4 (10.0–28.8) | 7.119 (1.673–30.288) | 0.008 | ||
| BCLC stage | A | 96.9 (93.4–100) | 80.1 (71.5–88.7) | 65.1 (50.2–80.0) | NR | <0.001 | - | NS |
| B | 89.5 (83.0–96.0) | 53.9 (42.3–65.5) | 40.0 (26.1–53.9) | 37.1 (24.2–50.1) | - | |||
| C | 75.0 (64.0–86.0) | 44.6 (31.5–57.7) | 32.2 (16.0–48.6) | 33.9 (16.2–51.7) | - | |||
| Diagnosis at PBT | Primary | 90.0 (71.4–100) | 56.0 (22.5–89.5) | 42.0 (7.5–76.5) | 38.4 (8.5–68.2) | 0.578 | - | NS |
| Recurrence | 88.8 (83.8–92.1) | 62.0 (55.3–68.7) | 48.2 (38.8–57.6) | 56.5 (45.3–67.7) | - | |||
| Pre-Tx to PBT site | No | 98.1 (94.4–100) | 82.3 (71.1–93.5) | 78.4 (65.3–91.5) | NR | <0.001 | - | NS |
| Yes | 86.4 (81.5–91.3) | 56.8 (49.4–64.2) | 41.7 (32.1–51.3) | 46.9 (33.7–60.1) | - | |||
| Pre-Tx to other site | No | 87.1 (79.3–94.9) | 54.0 (41.3–66.7) | 41.4 (26.3–56.5) | 38.4 (19.7–57.1) | 0.130 | - | NS |
| Yes | 89.6 (85.1–94.1) | 64.9 (57.3–72.5) | 51.2 (39.8–62.5) | NR | - | |||
| Concurrent Tx | No | 89.8 (85.9–93.7) | 62.8 (56.1–69.5) | 49.4 (38.0–60.8) | 56.5 (-) | 0.001 | - | NS |
| Sorafenib | 57.1 (20.4–93.8) | 28.6 (0–62.1) | 0 (-) | 19.4 (0–40.3) | - | |||
| Post-Tx to PBT site | No | 93.8 (90.5–97.1) | 67.5 (60.2–74.8) | 53.8 (42.6–65.0) | 60.3 (-) | <0.001 | - | NS |
| Yes | 68.7 (55.6–81.8) | 40.2 (25.9–54.5) | 26.2 (12.5–39.9) | 25.4 (7.1–43.7) | - | |||
| Post-Tx to other sites | No | 81.8 (72.6–91.0) | 68.8 (56.8–80.8) | 61.9 (45.2–78.6) | NR | 0.294 | - | NS |
| Yes | 91.5 (87.3–95.6) | 59.8 (52.2–67.4) | 44.3 (34.1–54.5) | 48.7 (36.3–61.1) | - | |||
| Dose-fractionation | Regimen A | 75.0 (61.7–88.3) | 33.3 (18.4–48.2) | 16.7 (3.6–29.8) | 23.4 (15.3–31.5) | <0.001 | 2.045 (1.244–3.362) | 0.005 |
| Regimen B | 86.7 (78.1–95.3) | 51.2 (38.1–64.3) | 39.2 (24.9–53.5) | 40.8 (19.7–61.9) | 1.298 (0.740–2.277) | 0.363 | ||
| Regimen C | 93.7 (89.8–97.6) | 76.0 (68.4–83.6) | 67.9 (57.5–78.3) | NR | 1.000 | |||
| Primary tumor response | CR | 97.0 (94.6–99.4) | 73.3 (66.6–80.0) | 60.9 (51.5–70.3) | NR | <0.001 | 1.000 | <0.001 |
| Non-CR | 52.3 (37.6–67.0) | 10.6 (1.0–20.2) | 0 (-) | 13.7 (10.8–16.6) | 7.012 (4.324–11.370) | |||